Biopharma feels momentary relief as Supreme Court preserves abortion drug access—for now

[{"selector":"#anim-1a1ba4e3-275b-47d5-ad5a-c76813e0ab15","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e1055d60-a30b-46d7-b71e-90c64a35663f","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. The Supreme Court has temporarily preserved access to the abortion medication mifepristone.

[{"selector":"#anim-31ca1ff2-2390-4855-901f-5a3267bfc1e0","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. The decision is seen as a victory for the biopharma industry that supported the FDA's authority to approve drugs.

[{"selector":"#anim-f2fc9879-6940-4897-ab0e-4c4320ee7221","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. Julia Owens, CEO of Ananke Therapeutics, highlights that the legal battle over mifepristone will continue.

[{"selector":"#anim-23b9d28c-272a-4ddf-834d-07464cc9a3d4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. The Biotech Sisterhood, a group of female industry executives, has been leading campaigns to protect abortion rights.

[{"selector":"#anim-88e24b60-6907-44bd-b334-54470a8d29a4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. They rallied support when a Texas judge blocked the FDA’s approval of mifepristone on April 7.

[{"selector":"#anim-6d7c3b57-921c-48dc-a2d6-df3b75f51717","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. A letter opposing the block garnered 700 signatures from industry members, including Pfizer CEO Albert Bourla.

[{"selector":"#anim-4078eece-5d0c-4ddc-96b5-0c06cc9039be","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. On April 21, the Supreme Court voted 7-2 to keep the abortion pill broadly available while the legal battle continues.

[{"selector":"#anim-0ca64b5f-a23a-401e-9e31-e4149a70f148","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. The biopharma industry was galvanized by concerns that the Texas ruling undermined the FDA's authority to approve medicines.

[{"selector":"#anim-6698cec0-87e6-4a46-87aa-11ef6455bfda","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. The issue of abortion rights should not be overshadowed by concerns about potential harm to drug development, according to Owens.

[{"selector":"#anim-07dfaef4-63d4-4a65-9bb8-4524aea6973e","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. The next court date concerning this issue is scheduled for May 17 at the U.S. Court of Appeals for the Fifth Circuit.

[{"selector":"#anim-84000399-8107-48c5-ac7f-94dff66b17a7","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-69fa3f9e-3d76-46a3-bd0c-cf5772d01795","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more